CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carroll, R. E.
Right arrow Articles by Benya, R. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carroll, R. E.
Right arrow Articles by Benya, R. V.
Cell Growth & Differentiation Vol. 11, 385-393, July 2000
© 2000 American Association for Cancer Research


Articles

Gastrin-releasing Peptide Is a Mitogen and a Morphogen in Murine Colon Cancer1

Robert E. Carroll, Kristina A. Matkowskyj, Maria S. Tretiakova, James F. Battey and Richard V. Benya2

Departments of Medicine [R. E. C., K. A. M., M. S. T., R. V. B.], Pathology [K. A. M.], and Pharmacology [R. V. B.] University of Illinois at Chicago, and Chicago Veterans Administration Medical Center (West Side Division) [R. E. C., K. A. M., M. S. T., R. V. B.], Chicago, Illinois 60612, and National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland 20892 [J. F. B.]

Abstract

Little is known about the factors involved in regulating the appearance, or differentiation, of solid tumors including those arising from the colon. We herein demonstrate that the mitogen gastrin-releasing peptide (GRP) is a morphogen, critically important in regulating the differentiation of murine colon cancer. Although epithelial cells lining the mouse colon do not normally express GRP and its receptor (GRP-R), both are aberrantly expressed by all better differentiated cancers in wild-type C57BL/6J mice treated with the carcinogen azoxymethane. Whereas small tumors in both wild-type and GRP-R-deficient (i.e., GRP-R-/-) mice are histologically similar, larger tumors become better differentiated in the former but degenerate into more poorly differentiated mucinous adenocarcinomas in the latter. This alteration in phenotype is attributable to GRP increasing focal adhesion kinase expression in GRP-R-expressing tumors. Consistent with GRP acting as a mitogen, GRP/GRP-R coexpressing tumors in wild-type animals also contain more proliferating cells than those occurring in GRP-R-/- mice. Yet tumors are similarly sized in animals of either genotype receiving azoxymethane for identical times, a finding attributable to the significantly higher number of apoptotic cells detected in GRP/GRP-R coexpressing cancers. Thus, these findings indicate that although GRP is a mitogen, aberrant expression does not result in increased tumor growth. Rather, the mitogenic properties of GRP are subordinate to it acting as a morphogen, where it and its receptor are critically involved in regulating colon cancer histological progression by promoting a well-differentiated phenotype.




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Qiao, J. Kang, T. A. Ishola, P. G. Rychahou, B. M. Evers, and D. H. Chung
Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma
PNAS, September 2, 2008; 105(35): 12891 - 12896.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya
International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States
Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
L. Taglia, D. Matusiak, K. A. Matkowskyj, and R. V. Benya
Gastrin-releasing peptide mediates its morphogenic properties in human colon cancer by upregulating intracellular adhesion protein-1 (ICAM-1) via focal adhesion kinase
Am J Physiol Gastrointest Liver Physiol, January 1, 2007; 292(1): G182 - G190.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
S. Glover, R. Nathaniel, L. Shakir, C. Perrault, R. K. Anderson, R. Tran-Son-Tay, and R. V. Benya
Transient upregulation of GRP and its receptor critically regulate colon cancer cell motility during remodeling
Am J Physiol Gastrointest Liver Physiol, May 12, 2005; 288(6): G1274 - G1282.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
D. Matusiak, S. Glover, R. Nathaniel, K. Matkowskyj, J. Yang, and R. V. Benya
Neuromedin B and its receptor are mitogens in both normal and malignant epithelial cells lining the colon
Am J Physiol Gastrointest Liver Physiol, March 11, 2005; 288(4): G718 - G728.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
P. Gelebart, T. Kovacs, J.-P. Brouland, R. van Gorp, J. Grossmann, N. Rivard, Y. Panis, V. Martin, R. Bredoux, J. Enouf, et al.
Expression of Endomembrane Calcium Pumps in Colon and Gastric Cancer Cells: INDUCTION OF SERCA3 EXPRESSION DURING DIFFERENTIATION
J. Biol. Chem., July 19, 2002; 277(29): 26310 - 26320.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. E. Carroll, D. Ostrovskiy, S. Lee, A. Danilkovich, and R. V. Benya
Characterization of Gastrin-Releasing Peptide and Its Receptor Aberrantly Expressed by Human Colon Cancer Cell Lines
Mol. Pharmacol., September 1, 2000; 58(3): 601 - 607.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 2000 by the American Association of Cancer Research.